Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - pravastatin sodium, quantity: 10 mg - tablet, film coated - excipient ingredients: lactose monohydrate; crospovidone; sodium bicarbonate; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; macrogol 8000; purified talc; iron oxide yellow - 1. as an adjunct to diet for the treatment of hypercholesterolaemia. prior to initiating therapy with pravastatin-lupin, secondary causes of hypercholesterolaemia (eg, poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. 2. pravastatin-lupin is indicated in patients with previous myocardial infarction including those who have normal (4.0-5.5 mmol/l) serum cholesterol levels. 3. pravastatin-lupin is indicated in patients with unstable angina pectoris (see clinical trials). 4. pravastatin-lupin is indicated as an adjunct to diet and lifestyle modification for the treatment of heterozygous familial hypercholesterolaemia in children and adolescent patients aged 8 years and older (see clinical trials).

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - ethambutol hydrochloride, quantity: 400 mg - tablet, film coated - excipient ingredients: ethylcellulose; magnesium stearate; titanium dioxide; polyethylene glycol monomethyl ether; povidone; purified talc; propylene glycol; hypromellose; maize starch; colloidal anhydrous silica - ethambutol lupin is indicated for the treatment of pulmonary tuberculosis, as shown by a large number of studies by investigators throughout the world. it has also been used successfully in cases of primary tuberculosis and extrapulmonary forms of tuberculosis, including miliary tuberculosis, tuberculous meningitis, tuberculosis of bones and joints, genitourinary tuberculosis, tuberculosis of the skin and tuberculous eye diseases. it should not be used as the sole antituberculosis drug, but should be used in conjunction with at least one other antituberculosis drug. selection of the companion drug should be based on clinical experience, considerations of comparative safety and appropriate in vitro susceptibility studies.,in patients who have not received previous antituberculosis therapy, i.e. initial treatment, the most frequently used regimens have included three of the following drugs ? ethambutol, isoniazid, rifampicin and streptomycin - for the first 2-4 months. for example:,? ethambutol plus isoniazid plus rifampicin; or ? ethambutol plus isoniazid plus streptomycin,then continuing with a two drug regimen such as,? ethambutol plus isoniazid; or ? ethambutol plus rifampicin.,in patients who have received previous antituberculosis therapy, mycobacterial resistance to other drugs used in initial therapy is frequent. consequently, in such retreatment cases ethambutol lupin should be combined with at least one of the second-line drugs not previously administered to the patient and to which bacterial susceptibility has been indicated by appropriate in vitro studies. antituberculosis drugs used with ethambutol have included cycloserine, ethionamide, pyrazinamide, viomycin and other drugs. isoniazid, aminosalicylic acid, and streptomycin have also been used in multiple drug regimens. alternating drug regimens have also been utilised.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - ethambutol hydrochloride, quantity: 400 mg - tablet, film coated - excipient ingredients: maize starch; propylene glycol; hypromellose; colloidal anhydrous silica; purified talc; povidone; magnesium stearate; titanium dioxide; ethylcellulose; polyethylene glycol monomethyl ether - ethambutol lupin is indicated for the treatment of pulmonary tuberculosis, as shown by a large number of studies by investigators throughout the world. it has also been used successfully in cases of primary tuberculosis and extrapulmonary forms of tuberculosis, including miliary tuberculosis, tuberculous meningitis, tuberculosis of bones and joints, genitourinary tuberculosis, tuberculosis of the skin and tuberculous eye diseases. it should not be used as the sole antituberculosis drug, but should be used in conjunction with at least one other antituberculosis drug. selection of the companion drug should be based on clinical experience, considerations of comparative safety and appropriate in vitro susceptibility studies.,in patients who have not received previous antituberculosis therapy, i.e. initial treatment, the most frequently used regimens have included three of the following drugs ? ethambutol, isoniazid, rifampicin and streptomycin - for the first 2-4 months. for example:,? ethambutol plus isoniazid plus rifampicin; or ? ethambutol plus isoniazid plus streptomycin,then continuing with a two drug regimen such as,? ethambutol plus isoniazid; or ? ethambutol plus rifampicin.,in patients who have received previous antituberculosis therapy, mycobacterial resistance to other drugs used in initial therapy is frequent. consequently, in such retreatment cases ethambutol lupin should be combined with at least one of the second-line drugs not previously administered to the patient and to which bacterial susceptibility has been indicated by appropriate in vitro studies. antituberculosis drugs used with ethambutol have included cycloserine, ethionamide, pyrazinamide, viomycin and other drugs. isoniazid, aminosalicylic acid, and streptomycin have also been used in multiple drug regimens. alternating drug regimens have also been utilised.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - escitalopram oxalate -

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - escitalopram oxalate -

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - zolpidem tartrate, quantity: 10 mg - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; sodium starch glycollate type a; hypromellose; magnesium stearate; titanium dioxide; macrogol 400 - zolpidem tartrate is indicated for the short term treatment of insomnia in adults (see dosage and administration).

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - duloxetine hydrochloride, quantity: 67.36 mg - capsule, enteric - excipient ingredients: croscarmellose sodium; purified talc; pregelatinised maize starch; lactose monohydrate; hypromellose; triethyl citrate; polysorbate 80; isopropyl alcohol; hypromellose phthalate; magnesium stearate; dichloromethane; methanol; titanium dioxide; propylene glycol; butan-1-ol; purified water; shellac; ethanol absolute; ammonia; potassium hydroxide; iron oxide yellow; gelatin; acetic acid; silicon dioxide; sodium lauryl sulfate; citric acid; indigo carmine aluminium lake; ethanol; strong ammonia solution; iron oxide black - duloxetine hydrochloride is indicated for the following:,-treatment of major depressive disorder (mdd). ,-treatment of generalised anxiety disorder (gad).

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - duloxetine hydrochloride, quantity: 33.68 mg - capsule, enteric - excipient ingredients: hypromellose phthalate; triethyl citrate; lactose monohydrate; croscarmellose sodium; dichloromethane; polysorbate 80; hypromellose; pregelatinised maize starch; magnesium stearate; methanol; purified talc; isopropyl alcohol; titanium dioxide; propylene glycol; butan-1-ol; purified water; shellac; ethanol absolute; ammonia; potassium hydroxide; ethanol; strong ammonia solution; iron oxide black; indigo carmine; gelatin; acetic acid; silicon dioxide; sodium lauryl sulfate; citric acid - duloxetine hydrochloride is indicated for the following:,-treatment of major depressive disorder (mdd). ,-treatment of generalised anxiety disorder (gad).

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - memantine hydrochloride -

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - memantine hydrochloride -